N/A N=4,240 Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
Lung Neoplasms
Primary: Number of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Biomarker — 45; 1346; 21; 38 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=450 Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Cancer
Primary: Proportion of Patients Being Receiving Treatment Administration After Diagnosis — 372 Participants
N/A N=153 Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Infectious Disease · Cancer · Coronavirus Infection
Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=25 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
N/A N=23 App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer
Cancer
Primary: Interviews — 20 Interviews
N/A N=60 PeLear CCC: Proyecto Latino Contra Cancer Colorrectal
Colorectal Cancer · Rectal Cancer · Colon Cancer
Primary: Attitudes Regarding Participation in Clinical Trials-Conceptual Themes (General Clinical Trials) — 85; 80 percentage of participants
N/A N=4,322 Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System
Breast Cancer · Colorectal Cancer
Primary: Proportion of Complex Cancer Survivors Meeting Quality of Care Guidelines for Chronic Conditions and Follow-up Cancer Surveillance
N/A N=76 National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
Non-small Cell Lung Cancer
Primary: Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations — 80; 0; 50; 28.6 percentage of participants
N/A N=3,051 S1204, Viral Screening in Newly Diagnosed Cancer Patients
Cancer
Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants
N/A N=1,102 Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic
COVID-19
Primary: Number and Severity of Confirmed COVID-19 Infections Among Cancer Centre Staff and Patients at 12 Months — 55; 36 Participants
Phase 3 N=112 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
Lung Neoplasms · Lung Cancer
Primary: Clinically Significant Events (CSE) — .530 proportion of participants
Phase 2 N=51 PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
Adenocarcinoma · Colorectal Cancer · Ovarian Cancer
Primary: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts…
Phase 1 N=313 Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Advanced Solid Tumors · Head and Neck Cancer · Pancreatic Cancer
Primary: Safety: Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT) (Phase 1a) — 0; 0; 1…
N/A N=6,400 Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing
Early Cancer Detection
Primary: Study Data and Samples Were Used for CancerSEEK Assay Development — 712; 3870; 5; 14 Participants
N/A N=175 Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America
HIV Infection · Human Immunodeficiency Virus 1 Positive · Malignant Neoplasm
Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…
N/A N=27 Cannabis Use in Cancer Patients
Solid Tumor, Adult
Primary: Likelihood of Accruing Participants: Feasibility of Enrollment — 27; 24 Participants
Phase 2 N=11 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Melanoma · Meningioma · Breast Cancer
Primary: Percentage of Participants With a Response — 10; 50 percentage of participants
N/A N=35,953 Cancer Prevention Clinical Decision Support
Cancer Prevention
Primary: Composite Cancer Screening Tests up to Date — 3087; 2590; 3866 Participants — p=.025
N/A N=580 An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
N/A N=15 Evaluation of Efficiency in Cancerology of New Technologies as Telemedicine and Conected Objects (e-DomSanté)
Breast Cancer
Primary: Quality of Life of the Patients at 12 Months — 59 score on a scale
Phase 2 N=12 TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
Breast Cancer
Primary: The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion)…
N/A N=35 CairnSurgical Breast Cancer Locator (BCL) Post-Market Study
Breast Cancer
Primary: Positive Margin Rate — 2 Participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
N/A N=303 Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Smoking Cessation
Primary: Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months — 29; 51 Participants
Phase 2 N=12 Dose Finding Safety Study of VAL201 in Cancer Patients
Stage III Prostate Carcinoma · Stage IV Prostate Carcinoma
Primary: Dose-Limiting Toxicity — 0; 0; 0; 0 Participants
N/A N=10 EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
Metastatic Pancreatic Cancer · Unresectable Pancreatic Cancer · Metastatic Colorectal Cancer
Primary: Number of Participants With Accurate Understanding of Chemotherapy Benefits at 8-12 Weeks — 0; 0 Participants
N/A N=14 Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
N/A N=41 Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®
Lung Cancer · Neoplasms, Lung · Neoplasms, Pulmonary
Primary: Feasibility of Self-reporting Symptoms Using Moovcare® — 66.0 percentage of e-PRO surveys completed
N/A N=182 A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer
Lung Cancer · Esophageal Cancer
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Scores. — 43.05; 51.51; 48.64; 50.74 units on a scale — p=<0.05